1 enrolling by invitation. 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 1 | Enrolling by invitation 1 |
Follow Microvascular Inflammation: new trials by email Literature Review of Microvascular Inflammation trials Research Report on Microvascular Inflammation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Learn More About the Long-Term Safety and Effects of Felzartamab Infusions in Adults With Kidney Transplants Who Have Antibody-Mediated Rejection (AMR) or Microvascular Inflammation (MVI) (TRANSCEND/TRANSPIRE LTE) Felzartamab - Antibody-mediated Rejection, Microvascular Inflammation | Phase 3 | Enrolling by invitation | Biogen | 201 | 2026-04-16 | 2026-10-09 |
felzartamab (1)
Biogen (1)
United States (1)